Capecitabine
- Generic Name
- Capecitabine
- Brand Names
- Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C15H22FN3O6
- CAS Number
- 154361-50-9
- Unique Ingredient Identifier
- 6804DJ8Z9U
- Background
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
- Indication
Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemotherapy perioperative treatment of adult locally advanced rectal cancer. For breast cancer, capecitabine is indicated for advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated or as a regimen with docetaxel after disease progression on prior anthracycline-containing chemotherapy. For gastric, esophageal, or gastroesophageal junction (GEJ) cancer, capecitabine is indicated as a component of a combination chemotherapy treatment for the treatment of adult unresectable or metastatic gastric, esophageal, or GEJ cancer or adult HER2-overexpressing metastatic gastric or GEJ adenocarcinoma who have not received prior treatment for metastatic disease. Finally, for pancreatic cancer, capecitabine is indicated as adjuvant treatment for adult pancreatic adenocarcinoma as a component of a combination chemotherapy regimen.
- Associated Conditions
- Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
- Associated Therapies
- Chemotherapy
Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2008-02-13
- Last Posted Date
- 2016-08-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT00614653
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy and Intensity-Modulated Radiation Therapy in Treating Patients Undergoing Surgery for Locally Advanced Rectal Cancer
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2008-02-12
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 79
- Registration Number
- NCT00613080
- Locations
- 🇺🇸
Piedmont Hospital, Atlanta, Georgia, United States
🇺🇸Regional Cancer Center at Singing River Hospital, Pascagoula, Mississippi, United States
🇺🇸Auburn Radiation Oncology, Auburn, California, United States
Perioperative Therapy for Resectable Pancreatic Cancer
- Conditions
- Adenocarcinoma of the PancreasStage IA Pancreatic CancerStage IB Pancreatic CancerStage IIA Pancreatic CancerStage IIB Pancreatic Cancer
- Interventions
- Drug: gemcitabine hydrochlorideDrug: docetaxelDrug: capecitabineRadiation: intensity-modulated radiation therapyDrug: oxaliplatinProcedure: pancreatic surgical procedureProcedure: therapeutic conventional surgeryOther: laboratory biomarker analysis
- First Posted Date
- 2008-02-07
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 35
- Registration Number
- NCT00609336
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Study of Capecitabine in Combination With SIR-Spheres in Patients With Advanced Cancer
- First Posted Date
- 2008-01-30
- Last Posted Date
- 2015-09-07
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 34
- Registration Number
- NCT00604409
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery
- Conditions
- Pancreatic Cancer
- Interventions
- Biological: panitumumabDrug: capecitabineDrug: fluorouracilDrug: gemcitabine hydrochlorideRadiation: radiation therapy
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 52
- Registration Number
- NCT00601627
- Locations
- 🇺🇸
Great Falls Clinic - Main Facility, Great Falls, Montana, United States
🇺🇸Mid Dakota Clinic, PC, Bismarck, North Dakota, United States
🇺🇸Illinois CancerCare - Canton, Canton, Illinois, United States
Imatinib, Capecitabine, and Cisplatin in Treating Patients With Unresectable or Metastatic Stomach Cancer
- Conditions
- Gastric Cancer
- Interventions
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2013-03-19
- Lead Sponsor
- Technical University of Munich
- Target Recruit Count
- 38
- Registration Number
- NCT00601510
- Locations
- 🇩🇪
Klinikum Rechts Der Isar - Technische Universitaet Muenchen, Munich, Germany
Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
- Conditions
- Gastrointestinal Carcinoid TumorIslet Cell Tumor
- First Posted Date
- 2008-01-28
- Last Posted Date
- 2013-08-07
- Target Recruit Count
- 84
- Registration Number
- NCT00602082
- Locations
- 🇬🇧
Basildon University Hospital, Basildon, England, United Kingdom
🇬🇧Addenbrooke's Hospital, Cambridge, England, United Kingdom
🇬🇧Mid Kent Oncology Centre at Maidstone Hospital, Maidstone, England, United Kingdom
Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma
- First Posted Date
- 2008-01-03
- Last Posted Date
- 2017-04-10
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT00585078
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma
- Conditions
- Gastrointestinal Cancer
- Interventions
- First Posted Date
- 2007-12-31
- Last Posted Date
- 2014-05-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 171
- Registration Number
- NCT00583674
Phase I/II Study of Panitumumab, Capecitabine and Oxaliplatin w EBRT for Esophageal Cancer
- Conditions
- Cancer of the Esophagus
- Interventions
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2015-07-02
- Lead Sponsor
- Brian Czito
- Target Recruit Count
- 29
- Registration Number
- NCT00578071
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.